HIV Infections: all 4,342 studies

Page 27 of 44. Open to participants first (242), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected PatientsCompletedNCT00943540Phase 2
• Integration of Family Planning and HIV Services in TanzaniaCompletedNCT00941876Not applicable
• Simplification From Protease Inhibitors to RaltegravirStatus unknownNCT00941083Phase 4
• Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 TrialWithdrawnNCT00936195Phase 3
• Study of Bone Disease in Older HIV-infected AdultsCompletedNCT00935935
• IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected PatientsCompletedNCT00935480Phase 3
• A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, AfricaCompletedNCT00931346Phase 1/2
• Integration of HIV Care and Treatment Into Antenatal Care in Migori District, KenyaCompletedNCT00931216Not applicable
• HIV Viral Load Monitoring in Resource-Poor SettingsCompletedNCT00929604Not applicable
• Natural History Study of HIV Acquired in Infancy or ChildhoodCompletedNCT00924365
• DDI Study of Etravirine and GSK1265744CompletedNCT00920296Phase 1
• Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe DrugsCompletedNCT00920088Phase 1
• Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC)CompletedNCT00918840
• Efficacy and Safety of Varenicline Among HIV-infected PatientsCompletedNCT00918307Phase 3
• Evaluation of Cardiovascular Effects of Smoking Cessation in HIV PatientsCompletedNCT00918073
• An Expanded Safety Study of Dapivirine Gel 4789 in AfricaCompletedNCT00917904Phase 1/2
• An Expanded Safety Study of Dapivirine Gel 4759 in AfricaCompletedNCT00917891Phase 1/2
• A Study of Anti-HIV Monoclonal Antibody KD-247CompletedNCT00917813Phase 1
• Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in KenyaCompletedNCT00914225
• Exercise for Patients With HIV InfectionsStatus unknownNCT00910936Phase 2/3
• TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)CompletedNCT00910806Phase 1
• Glutathione and Its Precursors in HIV-Infected PatientsCompletedNCT00910442Phase 2
• Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV TreatmentCompletedNCT00909129Not applicable
• PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.WithdrawnNCT00908414Phase 1
• Early Immune Responses to Vaccination - A Substudy to HVTN 205CompletedNCT00908323
• Evaluating an Exercise Program to Reduce Cardiovascular Risk Factors in Children Infected With HIVCompletedNCT00908284Not applicable
• Raltegravir in the Swiss HIV Cohort StudyCompletedNCT00904644
• Prevalence and Determinants of Chronic Obstructive Pulmonary Disease (COPD) in HIV+ PatientsCompletedNCT00904384
• Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV VaccineCompletedNCT00902824Phase 1
• Linkage to Care - Part IICompletedNCT00891644
• Empowerment Intervention for Young Women - Phase ICompletedNCT00891358Not applicable
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• Cognitive and Psychosocial Benefits of MISC Training for Ugandan ChildrenStatus unknownNCT00889395Not applicable
• Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) CapsidCompletedNCT00888446Phase 2
• Dose Reduction of Lopinavir in ChildrenCompletedNCT00887120Phase 2
• Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) RegimensCompletedNCT00886990
• HIV- Risk Reduction Behavioral Intervention for Commercial Sex Workers in Yerevan ArmeniaCompletedNCT00886561Phase 2
• Maraviroc in Immunological Non-Responder (INR) HIV-1-infected SubjectsCompletedNCT00884858Phase 4
• Testing an HIV Prevention Intervention for Psychiatric Patients in BrazilCompletedNCT00881699Phase 3
• Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-InfectionCompletedNCT00879047Phase 1
• Motiv82Change: an HIV Prevention Study for Young Latino MenCompletedNCT00877695Not applicable
• Maraviroc Immune Recovery StudyCompletedNCT00875368Phase 4
• Raltegravir and Atazanavir Dosing Strategy StudyCompletedNCT00874523Phase 3
• Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS PatientsStatus unknownNCT00872417Phase 4
• Determining Characteristics and Behaviors of Adolescent Women Regarding HIV Risk and Microbicide Trial ParticipationCompletedNCT00872261
• Anatomic and Visual Function Assessments on Asymptomatic HIV-positive PatientsCompletedNCT00871078
• Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating CenterCompletedNCT00870857
• Physician Focused Intervention to Improve Adherence With HIV AntiretroviralsCompletedNCT00870792Not applicable
• Measurement of Adherence to ART in HIV-Infected Children in Uganda (The CHARTA Study)CompletedNCT00868257
• Treatment De-Intensification and Residual HIV-1 in YouthCompletedNCT00867854
• Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/rCompletedNCT00866021Phase 4
• Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABCCompletedNCT00865475Phase 4
• Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With LipoatrophyCompletedNCT00865007Phase 4
• Raltegravir Activity In Lymphoid TissuesWithdrawnNCT00863668Not applicable
• Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?CompletedNCT00860977Phase 3
• Asha HIV Health Promotion Intervention in IndiaCompletedNCT00860769Phase 1/2
• Training Community Members to Deliver HIV Prevention Programs to Urban YouthCompletedNCT00859144Phase 3
• Safety Study of the HemoModulator System for the Treatment of Patients With Human Immunodeficiency Virus (HIV)Status unknownNCT00858923Phase 1
• Effect of Diet-induced Weight Loss on HIV-associated Metabolic SyndromeCompletedNCT00857298Not applicable
• Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-InfectionCompletedNCT00856154Phase 1
• Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal TissueCompletedNCT00855088Phase 1
• Pharmacotherapy for HIV Infected Patients With Alcohol ProblemsWithdrawnNCT00854230Phase 4
• Intensive Viral Dynamics Substudy of A5248CompletedNCT00852618
• Evaluating Post-test HIV Counseling Videos for TeensCompletedNCT00851539Not applicable
• A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult VolunteersCompletedNCT00851383Phase 1
• Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)CompletedNCT00850616Phase 1
• A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)CompletedNCT00849732Phase 1
• Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected MenCompletedNCT00846599
• Epidemiology and Pathogenesis of HIV-Associated Pulmonary HypertensionCompletedNCT00845013
• Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIVCompletedNCT00842634Phase 1
• ID and Testing Via Friendship NetworksCompletedNCT00841360
• A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and BrasilCompletedNCT00840905
• A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 ReplicationStatus unknownNCT00840762Phase 4
• Video-based Counseling & Rapid HIV Testing for TeensCompletedNCT00836550Not applicable
• Positive Lifestyles Using SafetyCompletedNCT00836290Not applicable
• Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug MonitoringStatus unknownNCT00836212Phase 4
• Cell Phone Intervention to Support Antiretroviral Therapy (ART) Adherence in KenyaCompletedNCT00830622Not applicable
• Interactions Between Antiretrovirals (ARVs) and Combined Oral Contraceptives (COCs)CompletedNCT00829114Phase 4
• The Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory Pilot StudyCompletedNCT00824278
• Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese VolunteersCompletedNCT00821535Phase 1
• Effective Aids Treatment and Support in the Free State (FEATS)Status unknownNCT00821366Phase 3
• Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive AdultsCompletedNCT00820846Phase 2
• Early and Intermittent Antiretroviral Therapy in Naive HIV Infected AdultsCompletedNCT00820118Phase 2
• Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.CompletedNCT00812318Phase 1
• Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/EmtricitabineCompletedNCT00808002Phase 3
• Impact of Different Contraceptives on the Immune System of HIV Infected Women in ZambiaCompletedNCT00807625Phase 2
• Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1CompletedNCT00807443Phase 2
• Examination of B Cell Responses in Human BloodCompletedNCT00806845
• Surveillance Cohort Long-term Toxicity Antiretrovirals in HIV-infected Patients Enrolled in TPV CohortWithdrawnNCT00805857
• Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV InfectionCompletedNCT00801879Phase 4
• Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 VectorCompletedNCT00801697Phase 1
• Micronutrients and Antioxidants in HIV InfectionCompletedNCT00798772Not applicable
• Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency VirusStatus unknownNCT00797030Phase 4
• Efficacy And Security Of Annual And Biennial Zoledronic Acid For Osteoporosis Treatment In An HIV-Infected Patients' CohortCompletedNCT00795483Phase 4
• The SASA! Study: An Evaluation of a Community Intervention to Address Gender-based Violence and Reduce HIV/AIDS Risk in UgandaStatus unknownNCT00790959Not applicable
• Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine TrialsTerminatedNCT00789789
• Integrase Resistance Analysis in HIV Patients Who Interrupted Raltegravir Due to Incomplete Viral SuppressionStatus unknownNCT00787774Not applicable
• Healthy Teen Girls: HIV Risk ReductionCompletedNCT00787696Phase 1/2
• Immune Responses in Patients Treated With RaltegravirWithdrawnNCT00785967Phase 3
• A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect AdherenceCompletedNCT00785616Phase 4

← HIV Infections overview